The American Society of Nephrology (ASN) 2012 Annual Meeting focused on the differences in differential diagnosis and treatment of lupus nephritis subtype 3G versus subtype 3S, which presents with segmental lesions of less than 50% of glomerular capillary collaterals, commonly with segmental necrosis, often as a manifestation of systemic vasculitis, when renal impairment progresses rapidly, systemic damage is severe, and response to common lupus treatment regimens is poor, but The prognosis can be significantly improved. 3G subtype shows spherical lesions exceeding 50% of the glomerular capillary collaterals, commonly sclerosis, and rarely necrotic changes, which generally do not require the aforementioned combined plasma purification treatment regimen, but respond less well to treatment than subtype 3S. When type IV LN has diffuse (>50%) glomerular crescent formation or vascular loop necrosis, if the patient has received previous CYC therapy and the cumulative dose is close to or above 36 g, although the KDIGO 2012 guidelines recommend MMF therapy, the author believes that plasma decontamination and/or immunoglobulin shock therapy should be administered concurrently.